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To examine any potential role for 1,25-dihydroxyvitamin D
(1,25(OH)2D) in inflammation associated with chronic kidney
disease we measured vitamin D metabolites, markers of
inflammation and gene expression in 174 patients with a
variety of kidney diseases. Urinary MCP-1 protein and renal
macrophage infiltration were each significantly but inversely
correlated with serum 1,25(OH)2D levels. Logistic regression
analysis with urinary MCP-1 as binary outcome showed that a
10-unit increase in serum 1,25(OH)2D or 25OHD resulted in
lower renal inflammation. Analysis of 111 renal biopsies found
that renal injury was not associated with a compensatory
increase in mRNA for the vitamin D-activating enzyme
25-hydroxyvitamin D-1a-hydroxylase (CYP27B1), its catabolic
counterpart 24-hydroxylase, or the vitamin D receptor. There
was, however, a significant association between tissue MCP-1
and CYP27B1. Patients with acute renal inflammation had a
significant increase in urinary and tissue MCP-1, macrophage
infiltration, and macrophage and renal epithelial CYP27B1
expression but significantly lower levels of serum 1,25(OH)2D in
comparison to patients with chronic ischemic disease despite
similar levels of renal damage. In vitro, 1,25(OH)2D attenuated
TNFa-induced MCP-1 expression by human proximal tubule
cells. Our study indicates that renal inflammation is associated
with decreased serum vitamin D metabolites and involves
activation of the paracrine/autocrine vitamin D system.
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The importance of vitamin D to renal physiology has been
recognized for many years. Synthesis of the active, hormonal
form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D),
from its inactive precursor (25-hydroxyvitamin D, 25OHD)
occurs primarily in the proximal tubules of the kidney1,2 and
supports the key endocrine actions of vitamin D.3 Recently, it
has become clear that 1,25(OH)2D has potent immunomo-
dulatory and antiproliferative properties, suggesting a role for
vitamin D in the pathophysiology of autoimmune disease,4
common cancers,5 hypertension,6,7 renal inflammation,8–10
and cardiovascular disease.6,11–13 Most of these nonclassical
actions have been attributed to autocrine synthesis of
1,25(OH)2D, without changes in serum 1,25(OH)2D levels.
Nevertheless, the kidney remains an integral component of
normal vitamin D metabolism and function, with the
vitamin D-activating enzyme 25-hydroxyvitamin D-1a-
hydroxylase (CYP27B1), its catabolic counterpart 24-hydro-
xylase (CYP24A1), and the nuclear vitamin D receptor
(VDR), involving in determining the circulating levels of
1,25(OH)2D.
1,14
In chronic kidney disease (CKD), perturbation of the
vitamin D hormonal system is associated with progressive
loss of renal function and may lead to skeletal,15 cardio-
vascular,12,13 and renal9 complications, contributing directly
to premature death.12,13 Although serum 1,25(OH)2D levels
decline early in CKD,16,17 mainly as a consequence of
decreased renal synthesis of the hormone, the predominant
defect that underlies this remains unclear. Abnormal
CYP27B1 activity may be due to: decreased kidney
mass,14,16–18 inhibition of CYP27B1 expression,19,20 dysregu-
lated CYP27B1 expression,21 or decreased availability of
substrate for CYP27B1.17 Circulating levels of 1,25(OH)2D
may also reflect aberrant activity of CYP24A1, which is
abundantly expressed in the kidney and catalyses conversion
of 1,25(OH)2D to inactive metabolites.
22,23 Another facet of
vitamin D that may impact significantly on CKD concerns is
its potent antiproliferative and immunomodulatory actions.
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For example, 1,25(OH)2D has been shown to modulate renal
inflammation and fibrosis.8–10,24 These processes have been
primarily attributed to the paracrine/autocrine effects of
vitamin D.10,25,26 However, other studies using vitamin D
analogs have indicated that the endocrine vitamin D system
may also contribute to immunomodulatory responses.8,9,24
Macrophage chemoattractant protein-1 (MCP-1) is ex-
pressed in injury and inflammation to direct macrophage
recruitment.27,28 1,25(OH)2D has been shown to be able to
inhibit this MCP-1 driven inflammatory process by blocking
nuclear factor-kB activation, potentially protecting the
kidney.29
In this work, we have used a cohort of kidney disease
patients to show for the first time a link between vitamin D
metabolism and renal inflammation.
RESULTS
Markers of renal impairment in a kidney disease population
undergoing renal biopsy
A total of 174 kidney disease patients (99 men, 75 women;
81.6% white, 10.9% Asian, 6.9% Afro-Caribbean) were
studied. Of these, 111 had frozen kidney biopsy tissue
available for PCR analysis. Data in Table 1 show clinical
parameters and Table 2 shows pathological diagnoses,
creatinine clearance (CrCl), and index of chronic damage.
The degree of renal impairment depended on disease
subclassification, with thin glomerular basement membrane
disease (TBMD) patients (CrCl: 103.4±34.2 ml/min; index
of chronic damage 2.2±3.5%) showing relatively intact renal
parenchyma (Table 2, Figure 3a and b) when compared with
renal vasculitis (25.9±39.4 ml/min; index of chronic damage
46.7±34.4%) or interstitial nephritis patients (CrCl:
11.3±12.0 ml/min; index of chronic damage 70.3±40.4%).
Bivariate analyses showed that CrCl correlated negatively
with the index of chronic renal damage (r¼ 0.665, Po0.001),
macrophage infiltration (r¼ 0.583, Po0.001), and urinary
MCP-1 concentration (r¼ 0.372, Po0.001) (data not
shown).
Renal impairment, renal inflammation, and the vitamin D
hormonal system
To relate the different markers of renal impairment outlined
in Tables 1 and 2, with serum and RNA measures of vitamin
D metabolism and function, we used several different
methods of comparison. With multiple linear regression
analysis, a negative correlation was observed between serum
1,25(OH)2D and renal scarring (b¼0.430, Po0.001) and
urinary MCP-1 levels (b¼0.179, P¼ 0.026). By contrast,
no correlation was observed between serum 1,25(OH)2D and
serum intact parathyroid hormone, a known regulator of the
renal vitamin D endocrine system. Serum 1,25(OH)2D also
correlated with serum 25OHD (b¼ 0.272, P¼ 0.001) (Table
3a), and, as expected, renal CYP27B1 mRNA correlated
positively with serum 1,25(OH)2D (b¼0.272, P¼ 0.012),
and showed no correlation with serum intact parathyroid
hormone (Table 3b). Although serum 1,25(OH)2D levels
correlated with renal impairment (Table 3a), no similar
association was observed for CYP27B1 mRNA and chronic
renal scarring (Table 3b) or CrCl (data not shown). CYP27B1
mRNA expression was negatively correlated with 24-h
urinary protein excretion (b¼ 0.349, P¼ 0.013), whereas
MCP-1 mRNA expression correlated positively with
CYP27B1 mRNA (b¼ 0.529, P¼ 0.002). To investigate
further, the effect of CKD on the expression of genes
associated with vitamin D metabolism and function, linear
regression analyses were carried out for CYP27B1, CYP24A1,
and VDR mRNAs. Data indicated that loss of renal mass,
declining serum 1,25(OH)2D levels, and deteriorating renal
function, as defined by CrCl and increasing chronic renal
damage, was not associated with altered expression of
mRNAs for CYP27B1, CYP24A1, or VDR (Figure 1).
Linear regression was also used to characterize further the
relationship between renal impairment and inflammation
with serum concentrations of 25OHD and 1,25(OH)2D
(Figure 2). The latter confirmed linear regression data in
Table 3a by showing a negative correlation with urinary
MCP-1 (r¼ 0.342, Po0.001), macrophage infiltration
(r¼ 0.537, Po0.001), renal scarring (r¼ 0.546, Po0.001)
(Figure 2a), and renal MCP-1 mRNA (r¼ 0.342, P¼ 0.003)
(data not shown). Serum 25OHD showed similar correlation
trends to 1,25(OH)2D but this was only statistically
significant for renal scarring (r¼ 0.343, Po0.001) (Figure
2b) and renal MCP-1 mRNA (r¼ 0.260, P¼ 0.024) (data not
shown). As an alternative model for correlation between renal
inflammation and serum vitamin D, logistic regression was
used, with urinary MCP-1 as a binary outcome variable
(Table 4). Previous studies from our group reported a mean
urinary MCP-1 of 245±243 pg/mg creatinine in a similar
CKD patient population with chronic inflammation.27
Therefore, to assess the potential role of vitamin D in a
more acute inflammatory environment, a ‘cut-off ’ value of
300 pg/mg creatinine for urinary MCP-1 was selected.
Comparing urinary MCP-1 p300 with 4300 mg/mg
creatinine, a 10 unit increase in serum 1,25(OH)2D reduced
the odds ratio (OR) to 0.75 (95% CI 0.65–0.88) for patients
Table 1 | Study population, n=174: clinical and pathological
characteristics
Median Range
Age (years) 52 18–89
Body mass index (kg/m2) 26.3 16.6–50.4
Systolic blood pressure (mm Hg) 137 90–200
Diastolic blood pressure (mm Hg) 75 45–106
Serum albumin (g/l) 40 10–50
Urea (mmol/l) 7.2 2.2–52.0
Serum creatinine (mmol/l) 126 51–1110
Hemoglobin (g/100 ml) 12.9 6.1–17.7
Leucocytes ( 106/ml) 6.8 2.3–35.4
Creatinine clearance (ml/min) 71.5 2–159
Index of chronic damage (%) 12.5 0–98
Urinary protein excretion (g/24 h) 0.12 0–18
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being in the group with higher urinary MCP-1, after
adjusting for age, gender, ethnicity, and index of chronic
renal damage (Table 4). The same observation was made for
serum 25OHD (OR 0.71; 95% CI 0.57–0. 90).
Dysregulation of the vitamin D hormonal system with
different forms of kidney disease
To provide an additional perspective on the vitamin D
hormonal system in CKD, data were also analyzed on the
basis of patient pathological/diagnostic groupings. The
TBMD group was selected as a control population with
minimal impaired renal function, scarring, and renal
inflammation. Patients with renal vasculitis or interstitial
nephritis were referred to as the acute inflammation group
(inflammation) and compared with the other three groups.
Patients in the acute inflammation had similar chronic renal
damage to the ischemia group (28 vs 32% of area, P¼NS)
(Figure 3b), but much lower levels of CrCl (7 vs 40 ml/min,
P¼ 0.001) (Figure 3a), higher macrophage infiltration (6.6 vs
1.8% of area, Po0.001) (Figure 3c), and higher urinary
MCP-1 (976.8 vs 143.9 pg/mg creatinine, Po0.001) (Figure
3d), reflecting the more acute, inflammatory nature of CKD
in these patients. Consistent with this, serum 1,25(OH)2D
levels were much lower in the inflammation group compared
with the ischemia patients (29.6 vs 67.1 pmol/l, P¼ 0.008)
(Figure 3e). However, there was no significant difference in
serum 25OHD levels between the groups studied (Figure 3f).
Analysis of biopsy tissue mRNA expression showed that levels
of renal CYP27B1 and at the same time probably also of
CYP24A1 and VDR were increased in acute renal inflamma-
tion (Figure 4).
In human kidney biopsies from patients with interstitial
nephritis, CYP27B1 protein expression was localized to areas
with immune cell infiltrate. Staining of consecutive sections
confirmed CYP27B1 protein to be colocalized to macro-
phages (CD68þVE cells) (Figure 5c–f). Strong CYP27B1
protein staining was also found in renal tubular cells near to
immune cell infiltration (Figure 5c,e). Normal kidney
expressed CYP27B1 protein along the tubules with almost
no immune cells in the renal interstitium (Figure 5a and b).
Regulation of MCP-1 expression by vitamin D in vitro
To investigate further a link between the vitamin D hormonal
system and renal inflammation, additional studies were
carried out in vitro. Results in Figure 6 showed that
inflammatory activation of proximal tubular epithelial cells
Table 2 | Study population: pathological diagnosis on the renal biopsy, creatinine clearance, and index of chronic renal damage
N
Creatinine clearance
(ml/min); mean (s.d.)
Index of chronic damage
(% area); mean (s.d.)
Chronic ischemic renal damage 44 50.1 (34.0) 38.1 (28.1)
Thin glomerular basement membrane disease 35 103.4 (34.2) 2.2 (3.5)
IgA nephropathy 27 80.2 (38.7) 19 (27.7)
Focal segmental sclerosing glomerulonephritis 14 81.2 (36.0) 17.3 (14.3)
Diabetic nephropathy 10 66.2 (46.6) 34.1 (28.4)
Renal vasculitis 9 25.9 (39.4) 46.7 (34.4)
Membranous nephropathy 7 76.9 (36.9) 40.5 (29.1)
Interstitial nephritis 6 11.3 (12.0) 70.3 (40.4)
Lupus nephritis 5 76.8 (47.8) 14.5 (17.2)
Nodular light-chain glomerulopathy with myeloma 4 39.1 (27.6) 52.0 (38.4)
Mesangioproliferative glomerulonephritis 3 93.7 (29.3) 0.0 (0.0)
Minimal change nephropathy 3 101.0 (25.5) —
Amyloidosis 2 38.0 (4.2) 49.5 (30.4)
Othera 5 35.9 (52.1) 47.5 (67.2)
Total 174 69.7 (42.5) 24.2 (28.4)
IgA, immunoglobulin A.
aOne iron overload, one metastatic carcinoma, two acute renal failure secondary to cardio-respiratory failure, and one histological diagnosis not made.
Table 3 | Correlates of serum 1,25(OH)2D and renal CYP27B1
mRNA expression in renal biopsy patients
Linear regression analysis (adjusted R2=0.377)
b P-values
(a) Serum 1,25-dihydroxyvitamin D
Constant NS
Index of chronic renal damage 0.430 o0.001
Serum 25(OH)D 0.272 0.001
Urinary MCP-1 protein 0.179 0.026
Intact PTH 0.045 NS
Linear regression analysis (adjusted R2=0.305)
(b) Renal CYP27B1 mRNA levels
Constant NS
Renal MCP-1 mRNA 0.529 0.002
Serum 1,25(OH)2D 0.408 0.012
Urinary protein in 24 h 0.349 0.013
Index of chronic renal damage 0.247 NS
Intact PTH 0.185 NS
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; MCP-1,
macrophage chemoattractant protein-1; NS, not significant; PTH, parathyroid hormone.
Linear regression analysis of correlation between serum 1,25(OH)2D (a) or CYP27B1
(b) and: (1) index of chronic renal damage (area in %); (2) serum 25-hydroxyvitamin
D (25OHD) (nmol/l); (3) serum 1,25(OH)2D (pmol/l); (4) urinary MCP-1 protein levels
(pg/mg creatinine); (4) renal tissue MCP-1 mRNA levels (dCT to 18S rRNA); (5) intact
PTH (pmol/l); (6) 24-h urinary protein (g/24 h). Results are presented for natural log
25OHD, natural log urinary MCP-1, natural log MCP-1 mRNA, natural log PTH, and
natural log 24-h urinary protein corrected serum calcium. Low mRNA tissue
expression is observed with increased dCT and vice versa. Significance of regression
is shown by Po0.05.
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Figure 1 | Effects of CKD on the expression of vitamin D-associated genes in renal biopsy tissue. Linear correlation between (a)
creatinine clearance (ml/min) and (b) histological measurement of an index of chronic renal damage within the renal biopsy specimen (area
in %) with renal expression of mRNAs for: CYP27B1, vitamin D receptor (VDR), and 24-hydroxylase (CYP24A1). All expression data are shown
as dCT values with respect to 18S rRNA. Low mRNA tissue expression is observed with increased dCT and vice versa. Correlation coefficient
is represented by r-value and statistical significance by P-value, with dotted lines representing 95% confidence intervals.
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with tumor necrosis factor-a stimulated MCP-1 production
by these cells, and this was attenuated following coincubation
with 1,25(OH)2D (P¼ 0.045), suggesting a possible role for
vitamin D as a modulator of renal inflammation.
DISCUSSION
Consistent with previously published studies, we confirmed
that increased renal impairment is associated with decreased
circulating levels of 1,25(OH)2D,
16–18 although this was not
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Figure 2 | Relationship between serum vitamin D metabolites and markers of renal inflammation and CKD. Linear correlation between
(a) serum 1,25(OH)2D (pmol/l) and (b) serum 25OHD (nmol/l) with: measurement of urinary MCP-1 protein levels (pg/mg creatinine, expressed as
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represented by r-value and statistical significance by P-value, with dotted lines representing 95% confidence intervals.
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associated with significant changes in CYP27B1 mRNA
expression. To the best of our knowledge, this is the first
study to describe the expression of vitamin D-related genes in
material from patients undergoing a diagnostic kidney
biopsy. As such, the only other available CKD model for
comparison is a rat model that has utilized three-fourth
nephrectomy, respectively, to mimic CKD.30 In these rats, the
renal impairment caused by substantial loss of renal mass was
associated with a compensatory increase in mRNA for
CYP27B1, and decreased expression of CYP24A1 and VDR
mRNA in the kidney remnant, with resulting normalized
serum 1,25(OH)2D levels. Clearly, it is difficult to draw a
direct comparison between the rat model and our data.
However, indirect measurement of renal endocrine function
in humans, with falling serum 1,25(OH)2D levels already as a
consequence of mild CKD seems to support our observa-
tions.16–18 One possible explanation for the lack of change in
CYP27B1 expression with renal impairment is that the
predominant determinant of decreased serum 1,25(OH)2D in
CKD patients is indeed loss of functional renal mass.
Alternatively, CKD may be associated with altered expression
of CYP27B1 and CYP24A1 mRNA splice variants that are not
readily detected by standard real-time RT–PCR but are still
able to modulate 25OHD metabolism.21,31 A further
explanation is that the analysis of mRNA for CYP27B1
mRNA does not adequately reflect changes in the protein for
this enzyme. Previous studies have shown that, during
normal physiology, there is a strong correlation between
expression of mRNA for CYP27B1 and capacity to synthesize
1,25(OH)2D.
32,33 However, more recent analysis of the
suppression of 1,25(OH)2D production in hypophosphate-
mic hyp mice concluded that control of CYP27B1 activity in
these animals occurred at a post-transcriptional level.34
Owing to the constraints of tissue availability, we were
unable to evaluate CYP27B1 protein expression or enzyme
activity in renal biopsies. It is therefore possible that the
decreased capacity for synthesis of 1,25(OH)2D associated
with CKD also involves a decline in protein rather than
mRNA for CYP27B1.
Data from this study indicate that another crucial
determinant of endocrine and autocrine 1,25(OH)2D in
CKD is serum 25OHD. Linear regression showed a strong
correlation between the active form of vitamin D and its
precursor, which contrasts the lack of direct correlation
between serum 25OHD and 1,25(OH)2D concentrations
previously reported in normal subjects.35 From this observa-
tion and the apparent retention of CYP27B1 expression
in situ, we can hypothesize that CKD patients with 25OHD
sufficiency will maintain adequate 1,25(OH)2D production.
A central question concerning the low levels of circulating
25OHD concentrations in CKD is whether this actively
contributes to renal inflammation with progression of renal
disease. To address the contribution of circulating 25OHD
concentration, renal inflammation and progression of renal
disease issue further, analysis of serum vitamin D metabolites
was carried out according to CKD disease type. Although
there was a trend toward lower levels of 25OHD in more
severe forms of CKD, we did not find a statistically significant
variation with disease severity. Nevertheless, these data
provide support for future studies to assess the impact of
vitamin D supplementation on changes in renal impairment
associated with CKD.
In CKD, a progressive decline in renal function is
associated with worsening tubulointerstitial and glomerular
scarring.36 Data presented here show a close association
between kidney function and the histological quantification
of tubulointerstitial fibrosis. Renal scarring is associated with
an immune cell infiltrate consisting primarily of macro-
phages,37 which increases with deteriorating renal function27
in response to local synthesis of the inflammatory chemokine
MCP-1, with accelerated tissue inflammation and in-
jury.27,37,38 This is illustrated by the high levels of macro-
phage infiltration and MCP-1 in acute renal inflammation,
which parallels the significant decline in renal impairment
seen in these patients. In the light of accumulating evidence
for the importance of the vitamin D hormonal system for the
modulation of local inflammation, in particular renal
inflammation,8–10,24,29 several of our observations are im-
portant, notably the logistic regression analyses (Table 4).
Although these data suggest that enhancement of the vitamin
D endocrine system is anti-inflammatory, it is also possible
that the effect of 25OHD is being mediated at a local,
autocrine/paracrine level. Specifically, characterization of the
acute inflammation disease group revealed increased expres-
sion of CYP27B1 mRNA and protein despite decreased
circulating levels of 1,25(OH)2D. Analysis of interstitial
infiltration by immune cells and immune staining of
consecutive tissue sections for macrophages and CYP27B1
protein suggests that activated macrophages are the likely
source of this enhanced CYP27B1 expression,39 although
renal epithelial cells26 and endothelial cells40 may also
contribute to localized synthesis of 1,25(OH)2D following
inflammation. The observed positive trend between
CYP27B1 and CYP24 mRNA in acute inflammation also
suggest a role for autocrine synthesis of 1,25(OH)2D, as
described for bone25 and is in contrast to its known
Table 4 | Logistic regression model for urinary MCP-1
Unadjusted B Unadjusted OR Adjusted* B Adjusted OR for a 10 unit increase in vitamin D
Serum 25OHD 0.024 0.98 (0.95–0.99) 0.034 0.71 (0.57–0.90)
Serum 1,25(OH)2D 0.028 0.97 (0.968–0.99) 0.028 0.75 (0.65–0.88)
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25OHD, 25-hydroxyvitamin D; MCP-1, macrophage chemoattractant protein-1; OR, odds ratio.
Urinary MCP-1 as binary outcome, comparing MCP-1 p300 with 4300 pg/mg creatinine for 25OHD (nmol/l) and 1,25(OH)2D (pmol/l). *The model was adjusted for age,
gender, ethnicity, index of chronic renal damage. OR with 95% confidence limits.
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Figure 3 | Analysis of renal biopsy patients according to disease diagnostic groups. Patients were grouped according to the
pathological diagnosis on renal biopsy (thin glomerular basement membrane disease (TBMD), n¼ 35; immunoglobulin A (IgA) nephropathy,
n¼ 27; chronic ischemic renal damage, n¼ 44 (ischemic); acute renal inflammation including the diagnosis of renal vasculitis and interstitial
nephritis, n¼ 15 (inflammation), and assessed for: (a) creatinine clearance (ml/min) following a 24-h urine collection, (b) index of chronic
renal damage (area in %), (c) histological quantification of interstitial macrophage infiltration (% of area of CD68þVE cells per area assessed),
(d) urinary MCP-1 protein levels (pg/mg creatinine), (e) serum 1,25(OH)2D (pmol/l), and (f) serum 25OHD (nmol/l) levels. Statistical
significance between groups is shown as P-values.
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regulation in renal tubular cells.25,26 Indeed, the addition of
exogenous 1,25(OH)2D was able to suppress TNF-a-induced
MCP-1 expression by renal epithelial cells in vitro, an effect
likely caused by 1,25(OH)2D targeting of nuclear factor-kB.
29
Renal conversion of 25OHD to 1,25(OH)2D may provide an,
as yet unrecognized, anti-inflammatory function for renal
CYP27B1 activity.
MATERIALS AND METHODS
Patient recruitment and tissue collection
Following local ethical committee approval (RRK2608), patients
underwent renal biopsy in the department of nephrology at the
Queen Elizabeth Hospital (Birmingham, UK), for investigation of
proteinuria and/or hematuria and/or renal impairment. Patients
taking vitamin D metabolites were excluded. Renal biopsy material
was divided and one part was snap frozen. The other part was fixed
in formalin–saline and glutaraldehyde for routine pathological study.
Relevant clinical data are shown in Table 1 and the main
pathological diagnoses are shown in Table 2.
Laboratory analysis
Serum and urinary creatinine was measured using the method of
Jaffe41 and CrCl calculated from a 24-h urine collection, performed
before renal biopsy. Urinary MCP-1 was quantified using a
commercially available sandwich ELISA kit (R&D Systems,
Minneapolis, MN, USA), and levels corrected for urinary creatinine.
Serum 25OHD (intraassay variation 5–6%, interassay variation
7–8%) (specificity for 25OHD2 75% and 25OHD3 100%)
and 1,25(OH)2D (intraassay variation 5–8%, interassay variation
9–10%) (specificity for 1,25(OH)2D2 91% and 1,25(OH)2D3 100%)
were measured using an IDS Gamma-B radioimmunoassay
(IDS, Boldon, UK). Intact parathyroid hormone was measured
using an immunoradiometric method, the Nichols intact para-
thyroid hormone assay (Nichols Institute Diagnostics, San
Clemente, CA, USA).
Quantitative (real-time) RT-PCR analysis of CYP27B1,
CYP24A1 VDR, and MCP-1 mRNA in renal biopsies
Total RNA was isolated from frozen kidney biopsies using the
GenElute RNA extraction system (Sigma, Poole, UK). Aliquots
(1.5 mg) of RNA from each biopsy were then reverse transcribed
using AMV reverse transcriptase (Promega, Southampton, UK).
Gene-specific PCR was then carried out using an ABI 7700 sequence
detection system (PE Biosystems, Warring, UK) as described
previously,42 using primers and probes outlined below under the
following conditions: 50 1C for 2 min; 95 1C for 10 min; followed by
44 cycles of 95 1C for 15 s and 60 1C for 1 min.
Primers and probes for PCR reactions
Primer and probe sequences for CYP27B1, VDR, and CYP24A1 were
as follows: CYP27B1, forward primer 50-TTGGCAAGCGCAGCTGT
AT-30, reverse primer 50-TGTGTTAGGATCTGGGCCAAA-30, Taq-
Man probe 50-TTGCAATTCAAGCTCTGCCAGGCG-30; VDR, for-
ward primer 50-CTTCAGGCGAAGCATGAAGC-30, reverse primer
50-CCTTCATCATGCCGATGTCC-30, TaqMan probe 50-AAGGCAC
TATTCACCTGCCCCTTCAA-30; CYP24A1, forward primer 50-CAA
ACCGTGGAAGGCCTATC-30, reverse primer 50-AGTCTTCCCCTT
CCAGGATCA-30, TaqMan probe 50-ACTACCGCAAAGAAGGCTAC
GGGCTG-30. The primers and probe for MCP-1 were commercially
available assays on demand (Applied Biosystems, UK).
Measurement of chronic kidney damage
An interactive image analysis system was used to outline
and measure the extent of glomerular and interstitial scarring,
expressed as percentage of cortical cross-sectional area, in biopsies
stained with periodic acid–methenamine silver. This measure,
the index of chronic damage, is a strong predictor of renal
outcome.36
0
2
4
6
8
10
12
14
16
0
1
2
3
4
5
6
0
1
2
3
4
TBMD
P = NS
P = NS P = 0.041
P = 0.07
P = 0.07
R
en
al
 C
YP
27
B1
 m
RN
A
e
xp
re
ss
io
n 
(co
mp
are
d w
ith
 TB
MD
)
InflammationIschemicIgA
TBMD InflammationIschemicIgA
TBMD InflammationIschemicIgA
R
en
al
 V
ita
m
in
 D
 re
ce
pt
or
 m
RN
A
e
xp
re
ss
io
n 
(co
mp
are
d w
ith
 TB
MD
)
R
en
al
 C
YP
24
A1
 m
RN
A
e
xp
re
ss
io
n 
(co
mp
are
d w
ith
 TB
MD
)
Figure 4 | Analysis of renal biopsy patients according to
disease diagnostic groups. Patients were grouped according to
pathological diagnosis on renal biopsy (thin glomerular basement
membrane disease (TBMD), n¼ 35; immunoglobulin A (IgA)
nephropathy, n¼ 27; chronic ischemic renal damage, n¼ 44
(ischemic); acute renal inflammation including the diagnosis of
renal vasculitis and interstitial nephritis, n¼ 9 (inflammation) and
assessed for renal biopsy expression of: (a) CYP27B1 mRNA, (b)
24-hydroxylase (CYP24A1) mRNA, and (c) vitamin D receptor
(VDR) mRNA. All expression data are shown as fold change in
levels of mRNA with respect to TBMD values. Statistical
significance between groups is shown as P-values.
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Analysis of macrophage infiltration and CYP27B1 expression
of renal tissue
Immunohistochemical detection of tissue macrophages and inter-
active image analysis was performed as previously described.27
Coded sections stained for CD68 were visualized at  200
magnification and the image captured digitally by an Aequitas
image database and image archive management system (Dynamic
Data Links, Cambridge, UK). Each image was then converted to a
a b
c d
e f
Figure 5 | Localization of CYP27B1 protein and macrophages by immunohistochemistry in paraffin sections from human kidney
biopsies. Immunohistochemistry (positive staining brown) for CYP27B1, (a) and macrophages (CD68þVE), (b) (consecutive sections) for
normal kidney; for CYP27B1, (c, e) and CD68þVE, (d, f) (consecutive sections) of kidneys from two different patients with interstitial nephritis.
Increased expression for CYP27B1 protein is found in areas of immune cell, particularly macrophage (CD68þVE) infiltration. Significant
CYP27B1 protein expression is also found in remnants of renal tubular cells. Magnification (a–d:  40, e–f:  80).
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two-color scale image by Aequitas image analysis software. By
altering the threshold, the image was processed so that positive
staining was represented by black pixels and measured as a
percentage of the area of total image analyzed. For each patient,
the mean measurement of five randomly selected nonconfluent
microscopic fields of renal cortex was determined. Glomerular
staining was excluded from the analysis by the computer software.
Sections where background staining made it impossible to digitally
differentiate specific staining were excluded from analysis. Immuno-
histochemical analysis of CYP27B1 protein on paraffine embedded
human kidney biopsies was performed using previously described
methods.43
Primary culture of human proximal tubular epithelial cells
Human proximal tubular epithelial cells were grown using described
methodologies.44 Cells were used up to three passages for
experimental treatments (24 h) included TNF-a (1 ng/ml),
1,25(OH)2D (10
–7
M) alone and TNF-a (1 ng/ml) with
1,25(OH)2D (10
–7
M). Epithelial MCP-1 production was quantified
with the commercially available sandwich ELISA kit according to
manufacturer’s (R&D Systems) instructions and levels corrected for
total cellular protein.
Statistical analysis
Data were expressed as mean±s.d. unless otherwise (threshold cycle
for amplification of the target gene (CT) minus CT for 18S rRNA)
stated. Statistical analysis on real-time PCR was performed on dCT
values. Importantly, the quantification of mRNA from the gene of
interest provides a larger difference to the house-keeping gene, when
fewer target mRNA can be found in tissue. This can lead to the
description of a negative association, where a positive association is
described and vice versa. Comparison between groups was under-
taken with paired and unpaired t-tests, analysis of variance, or the
Mann–Whitney rank-sum test where appropriate. Linear regression
analyses were performed to determine relationship between data
variables, with appropriate transformations of items with non-
normal distributions. Stepwise multivariable linear regression
analysis was performed to identify statistically significant predictors.
Final models were assessed for colinearity and regression diagnostics
checked to ensure models were reasonable fit to data. Relationships
are presented as standardized b-coefficient with the P-value.
Analyses were performed using SPSS for Windows, version 12.0,
and the level of significance was set at Po0.05.
Multiple logistic regression models allowed for adjustment of OR
for potential confounding effects of age, gender, ethnicity, and index
of chronic renal scarring. Logistic models were fitted using the
SAS statistical package and their appropriateness assessed using
Hosmer–Lemeshow goodness-of-fit tests and colinearity diagnostics.
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